Hayley Virgil | Authors


Adagrasib Reveals Efficacy in KRAS G12CMutated NSCLC

June 17, 2021

Updated findings from the early-stage KRYSTAL-1 study showed that treatment with adagrasib resulted in durable responses, broad disease control, and provided extensive predicted coverage throughout the dosing interval in patients with KRAS G12Cmutant advanced non–small cell lung cancer.

Responses Achieved With Zandelisib/Zanubrutinib in R/R CLL, B-Cell Lymphomas

June 14, 2021

A combination of zandelisib and zanubrutinib induced significant responses, including several complete responses in patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell lymphomas in a phase 1b study, the results of which were presented during the 2021 European Hematology Association Annual Congress.